

(12) International Application Status Report

Received at International Bureau: 01 April 2020 (01.04.2020)

Information valid as of: 25 August 2020 (25.08.2020)

Report generated on: 28 January 2021 (28.01.2021)

(10) Publication number:

WO2020/196381

(43) Publication date:

01 October 2020 (01.10.2020)

(26) Publication language:

Japanese (JA)

(21) Application Number:

PCT/JP2020/012649

(22) Filing Date:

23 March 2020 (23.03.2020)

(25) Filing language:

Japanese (JA)

(31) Priority number(s):

2019-064487 (JP)

(31) Priority date(s):

28 March 2019 (28.03.2019)

(31) Priority status:

Priority document received (in compliance with PCT Rule 17.1)

2019-194008 (JP)

25 October 2019 (25.10.2019)

Priority document received (in compliance with PCT Rule 17.1)

(51) International Patent Classification:

A61P 7/08 (2006.01); **A61K 9/08** (2006.01); **A61K 47/02** (2006.01); **A61K 47/12** (2006.01)

(71) Applicant(s):

OTSUKA PHARMACEUTICAL FACTORY, INC. [JP/JP]; 115 AzaKuguhara, Tateiwa, Muya-cho, Naruto-shi, Tokushima 7728601 (JP) *(for all designated states)*

(72) Inventor(s):

KOBAYASHI, Tadashi; c/o HIROSAKI UNIVERSITY, 1, Bunkyo-cho, Hirosaki-shi, Aomori 0368560 (JP)

MAITA, Hiroki; c/o HIROSAKI UNIVERSITY, 1, Bunkyo-cho, Hirosaki-shi, Aomori 0368560 (JP)

OHMURO, Hideki; c/o Otsuka Pharmaceutical Factory, Inc., 115 AzaKuguhara, Tateiwa, Muya-cho, Naruto-shi, Tokushima 7728601 (JP)

HIROTA, Yusuke; c/o Otsuka Pharmaceutical Factory, Inc., 115 AzaKuguhara, Tateiwa, Muya-cho, Naruto-shi, Tokushima 7728601 (JP)

HARADA, Daisuke; c/o Otsuka Pharmaceutical Factory, Inc., 115 AzaKuguhara, Tateiwa, Muya-cho, Naruto-shi, Tokushima 7728601 (JP)

HAYASHI, Takehito; c/o Otsuka Pharmaceutical Factory, Inc., 115 AzaKuguhara, Tateiwa, Muya-cho, Naruto-shi, Tokushima 7728601 (JP)

MORITA, Tomoki; c/o Otsuka Pharmaceutical Factory, Inc., 115 AzaKuguhara, Tateiwa, Muya-cho, Naruto-shi, Tokushima 7728601 (JP)

SHINAGAWA, Yoshiyuki; c/o Otsuka Pharmaceutical Factory, Inc., 115 AzaKuguhara, Tateiwa, Muya-cho, Naruto-shi, Tokushima 7728601 (JP)

(74) Agent(s):

TANAKA, Junya; 21st Floor, Nakanoshima Intes Bldg., 6-2-40, Nakanoshima, Kita-ku, Osaka-shi, Osaka 5300005 (JP)

(54) Title (EN): INFUSION FOR SUBCUTANEOUS ADMINISTRATION

(54) Title (FR): PERFUSION POUR ADMINISTRATION SOUS-CUTANÉE

(54) Title (JA): 皮下投与用輸液

(57) Abstract:

(EN): An objective of the present invention is to provide an infusion of improved subcutaneous diffusivity. Bicarbonate ions are included in the infusion for subcutaneous administration to improve the subcutaneous diffusivity of the infusion for subcutaneous administration. The infusion for subcutaneous administration is preferably in the form of Ringer's solution having a bicarbonate ion concentration of 10-50 mEq/L, a pH of 6.0-8.5, an osmolality ratio of 0.8-1.3 with respect to the osmolality of normal saline, and a dosage of 20-1500 ml/day, and can further contain sodium ions, potassium ions, calcium ions, magnesium ions, and citrate ions.

(FR): Un objectif de la présente invention est de fournir une perfusion à diffusivité sous-cutanée améliorée. Des ions bicarbonate sont inclus dans la perfusion pour une administration sous-cutanée afin d'améliorer la diffusivité sous-cutanée de la perfusion pour

une administration sous-cutanée. La perfusion pour administration sous-cutanée se présente de préférence sous la forme d'une solution de Ringer ayant une concentration en ions bicarbonate de 10 à 50 mEq/L, un pH de 6,0 à 8,5, un rapport d'osmolalité de 0,8 à 1,3 par rapport à l'osmolalité d'une solution saline normale, et une posologie de 20 à 1 500 ml/jour, et peut en outre contenir des ions sodium, des ions potassium, des ions calcium, des ions magnésium et des ions citrate.

(JA): 本発明は、皮下拡散性が向上した輸液を提供することを目的とする。皮下投与用輸液において重炭酸イオンを配合することで、皮下投与用輸液の皮下拡散性が向上する。皮下投与用輸液は、好ましくは、重炭酸イオンの濃度が10～50mEq/L、pHが6.0～8.5、生理食塩水の浸透圧に対する浸透圧比が0.8～1.3、投与量が20～1500ml/日であり、リンゲル液の形態であり、更に、ナトリウムイオン、カリウムイオン、カルシウムイオン、マグネシウムイオン、クエン酸イオンを含むことができる。

International search report:

Received at International Bureau: 15 June 2020 (15.06.2020) [JP]

International Report on Patentability (IPRP) Chapter II of the PCT:

Not available

(81) Designated States:

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW

European Patent Office (EPO) : AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

African Intellectual Property Organization (OAPI) : BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG

African Regional Intellectual Property Organization (ARIPO) : BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW

Eurasian Patent Organization (EAPO) : AM, AZ, BY, KG, KZ, RU, TJ, TM